[1]

Zhang Y, Chen J, She Y, Fang Z, Zhang Y, et al. 2026. Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer. Cancer Cell 44:77−93.e78

doi: 10.1016/j.ccell.2025.10.010
[2]

Feng J, Hu Z, Xia X, Liu X, Lian Z, et al. 2023. Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer. Oncogene 42:1620−1633

doi: 10.1038/s41388-023-02676-9
[3]

Ruan DY, Wu HX, Xu Y, Munster PN, Deng Y, et al. 2025. Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation. Signal Transduction and Targeted Therapy 10:189

doi: 10.1038/s41392-025-02274-z
[4]

Desai J, Alonso G, Kim SH, Cervantes A, Karasic T, et al. 2024. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. Nature Medicine 30:271−278

doi: 10.1038/s41591-023-02696-8
[5]

Amodio V, Yaeger R, Arcella P, Cancelliere C, Lamba S, et al. 2020. EGFR blockade reverts resistance to KRASG12C inhibition in colorectal cancer. Cancer Discovery 10:1129−1139

doi: 10.1158/2159-8290.Cd-20-0187
[6]

Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, et al. 2019. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. British Journal of Cancer 121:725−737

doi: 10.1038/s41416-019-0573-8
[7]

Yaeger R, Mezzadra R, Sinopoli J, Bian Y, Marasco M, et al. 2023. Molecular characterization of acquired resistance to KRASG12C–EGFR inhibition in colorectal cancer. Cancer Discovery 13:41−55

doi: 10.1158/2159-8290.Cd-22-0405
[8]

Chong CR, Jänne PA. 2013. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nature Medicine 19:1389−1400

doi: 10.1038/nm.3388
[9]

Moorman A, Benitez EK, Cambulli F, Jiang Q, Mahmoud A, et al. 2025. Progressive plasticity during colorectal cancer metastasis. Nature 637:947−954

doi: 10.1038/s41586-024-08150-0
[10]

Quintanal-Villalonga Á, Chan JM, Yu HA, Pe'er D, Sawyers CL, et al. 2020. Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nature Reviews Clinical Oncology 17:360−371

doi: 10.1038/s41571-020-0340-z
[11]

Wallaeys C, Garcia-Gonzalez N, Libert C. 2023. Paneth cells as the cornerstones of intestinal and organismal health: a primer. EMBO Molecular Medicine 15:EMMM202216427

doi: 10.15252/emmm.202216427
[12]

Sakahara M, Okamoto T, Srivastava U, Natsume Y, Yamanaka H, et al. 2024. Paneth-like cells produced from OLFM4+ stem cells support OLFM4+ stem cell growth in advanced colorectal cancer. Communications Biology 7:27

doi: 10.1038/s42003-023-05504-8
[13]

Sasaki N, Sachs N, Wiebrands K, Ellenbroek SIJ, Fumagalli A, et al. 2016. Reg4+ deep crypt secretory cells function as epithelial niche for Lgr5+ stem cells in colon. Proceedings of the National Academy of Sciences of the United States of America 113:E5399−E5407

doi: 10.1073/pnas.1607327113
[14]

Schuler M, Cho BC, Sayehli CM, Navarro A, Soo RA, et al. 2019. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. The Lancet Oncology 20:1454−1466

doi: 10.1016/S1470-2045(19)30412-7